3.1.3.86	malfunction	apoptosis in MDA-MB-231 cells is increased in SHIP2-depleted cells as compared to control cells	751180	
3.1.3.86	malfunction	cell adhesion to collagen-I-coated dishes is decreased in SHIP2-deicient MEF cells compared with wild type cells	714946	
3.1.3.86	malfunction	depletion of SHIP 5'-phosphatases increases neutrophil wound attraction and random motility through a PI3K-dependent pathway. Ectopic expression of the SHIP1 phosphatase domain impairs neutrophil migration	732045	
3.1.3.86	malfunction	disruption of the enzyme-Mena interaction in cancer cells leads to attenuated capacity for extracellular matrix degradation and invasion in vitro, as well as reduced metastasis in vivo	751174	
3.1.3.86	malfunction	enzyme deficiency leads to myeloproliferation and B-cell lymphoma in mice	751768	
3.1.3.86	malfunction	enzyme depletion inhibits cell migration of glioblastoma cells	751179	
3.1.3.86	malfunction	enzyme mutations are associated with opsismodysplasia. Mice expressing a germline catalytically inactive SHIP2 mutant protein are viable, but have defects in the development of muscle, adipose tissue and the female genital tract, as well as in somatic growth	750315	
3.1.3.86	malfunction	isoform SHIP2 inhibition or knockdown inhibits cell migration and reduces phosphorylated protein kinase B levels, resulting in sensitivity to chemotherapeutics	751770	
3.1.3.86	metabolism	the enzyme participates in the insulin signalling pathway in vivo	679146	
3.1.3.86	physiological function	high glucose induces SHIP2 mRNA and protein levels in HepG2 cells. Overexpression of a dominant negative mutant SHIP2 ameliorates high glucose-induced de novo lipogenesis and secretion of apoB containing lipoprotein in HepG2 cells. Overexpression of the SHIP2 dominant negative mutant decreases high glucose-induced apoB containing lipoproteins secretion via reduction in reactive oxygen species generation, JNK phosphorylation and Akt activation. AMPK/mTOR/SREBP1 is the signaling pathway that mediates the effects of SHIP2 modulation on hepatic de novo lipogenesis	750611